

SUPPLEMENTARY TABLES

Supplementary Table I. Summary of phenotyping result of canine lymphoma samples.

Sample ID	Histological Classification ^a	CD20 (6C8)	CD21	CD22	CD3	CD5	CD4	CD8	CD45
DLYM-0902	DLBCL	++	++	++	-	-	-	-	+++
DLYM-1001	DLBCL	++	++	++	-	-	-	-	+++
DLYM-1002	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1003	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1004	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1005	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1007	MZL	+++	+++	+++	-	-	-	-	+++
DLYM-1009	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1012	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1013	DLBCL ^b	+++	+++	+++	-	-	-	-	+++
DLYM-1014	DLBCL	+	+	++	-	-	-	-	+++
DLYM-1015	BL	+++	++	++	-	-	-	-	+++
DLYM-1016	DLBCL	++	+	++	-	-	-	-	+++
DLYM-1017	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1018	DLBCL ^b	+++	+++	+	-	-	-	-	+++
DLYM-1101	BL	+++	+++	+++	-	-	-	-	+++
DLYM-1102	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1103	DLBCL	++	++	++	-	-	-	-	+++
DLYM-1104	MZL	++	++	++	-	-	-	-	+++
DLYM-1106	MZL	+	+	+	-	-	-	-	+++
DLYM-1107	DLBCL	+++	+++	+++	-	-	-	-	+++
DLYM-1108	DLBCL	+	+	+	-	-	-	-	+++
DLYM-0901	TZL	-	-	-	+	+	+	-	+++
DLYM-1006	PTCL	-	-	-	+	±	+	-	+++
DLYM-1008	TZL	-	+++ ^c	-	+	+	-	±	-
DLYM-1010	PTCL	-	-	-	+++	-	±	-	+++
DLYM-1011	TZL	-	+++ ^c	-	+++	++	-	-	-
DLYM-1019	TZL	-	+++ ^c	-	++	++	-	±	+++
DLYM-1105	PTCL	-	-	-	+	±	-	±	+++

The percentage of cells that express indicated CD molecule in total cells was determined using flow cytometry. -: <30%, ±; 30-70%, +; >70%, ++; >80%, +++; >90%.

^a DLBCL; diffuse large B-cell lymphoma, MZL; marginal-zone lymphoma, BL; Burkitt lymphoma, TZL; T-zone lymphoma, PTCL; peripheral T-cell lymphoma not otherwise specified.

^b These samples were not clearly distinguishable from late-stage MZL.

^c The expression of CD21 (complement receptor 2 or CR2) was previously reported in canine TZL. [Frantz AM, Sarver AL, Ito D, et al. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol 2013;50:693-703.]

Supplementary Table II. Summary of direct cytotoxicity assay using primary canine B-cell lymphoma cells.

Sample ID	IgG1/No Ab	6C8/No Ab
DLYM-1004	102.2	112.4
DLYM-1005	99.1	101.8
DLYM-1016	99.3	102.6
DLYM-1103	99.6	117.4
Mean \pm S.E.M.	100.1 \pm 0.7	108.5 \pm 3.8 ^d

The percent of live cells normalized to the number of cells present at the end of the culture period in the conditions with no antibody treatment is shown.

^dThere were no statistically significant differences in cell viability in cells treated with IgG1 and 6C8 (two-tailed t test for paired samples).

Supplementary Table III. Summary of complement-dependent cytotoxicity using primary canine B-cell lymphoma cells.

Sample ID	IgG1+RC/RC	6C8+RC/RC
DLYM-1004	87.3	78.1
DLYM-1005	101.6	100.7
DLYM-1016	84.6	90.9
Mean \pm S.E.M.	91.1 \pm 5.3	89.9 \pm 6.5 ^e

The percent of live cells normalized to the number of cells present at the end of the culture period in the conditions with RC only treatment sample is shown.

^eThere were no statistically significant differences in cell viability in cells treated with IgG1 and 6C8 (two-tailed t test for paired samples).